Abstracts tagged "interleukins (IL) and rheumatoid arthritis"

Abstract Number: 467 • 2016 ACR/ARHP Annual Meeting
Interleukin-21-Signaling in B Cells, but Not in T Cells, Is Indispensable for Development of Collagen-Induced Arthritis in Mice
Koji Sakuraba^1,2, Kenjiro Fujimura^1,2, Hisaaki Miyahara¹ and Hisakata Yamada², ¹Clinical Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan, ²Division of Host Defense, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
Background/Purpose: IL-21 is a T cell-derived cytokine whose receptor is expressed on variety of cells in immune system. IL-21was reported to be involved in the…
Abstract Number: 2351 • 2014 ACR/ARHP Annual Meeting
Ligand of Glucocorticoid-Induced Tumor Necrosis Factor Receptor Enhances Th17 Cells Response in Collagen-Induced Arthritis Via P38 MAPK and STAT3 Pathway
Xinyi Tang¹ and Shengjun Wang², ¹Department of Laboratory Medicine, Jiangsu University Affi�liated People’s Hospital, Zhenjiang, China, ²Department of Laboratory Medicine, Jiangsu University Affiliated People’s Hospital, Zhenjiang, China
Background/Purpose Helper T lymphocyte-17 (Th17) has recognized to be an important factor in rheumatoid arthritis (RA) pathogenesis. The natural ligand of glucocorticoid-induced tumor necrosis factor…
Abstract Number: 2216 • 2013 ACR/ARHP Annual Meeting
Tubastatin A, a Selective Histone Deacetylase-6 Inhibitor, Suppresses Synovial Inflammation and Joint Destruction In a Collagen Antibody-Induced Arthritis Mouse Model
Joong Kyong Ahn¹, Jaejoon Lee², Hyemin Jeong², Jiwon Hwang², Seulkee Lee², Ji Young Chai³, Inyoung Kim^2,4, Eun Chung Hong⁵, Eun-Kyung Bae⁵, Hoon-Suk Cha² and Eun-Mi Koh², ¹Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Division of Rheumatology, Jesang Hospital, Seongnam-si Gyeonggi-do, South Korea, ⁴MD, Seoul, South Korea, ⁵Samsung Biomedical Research Institute, Seoul, South Korea
Background/Purpose: Histone deacetylases (HDAC) play a key role in regulating gene expression by deacetylasing histones, and HDAC inhibitors induce various cellular effects, including apoptosis, cell…
Abstract Number: 2320 • 2012 ACR/ARHP Annual Meeting
Superantigen Induces IL-17 Production From Extremely Polarized Th1 Clones
Kentaro Yomogida¹, Yuan K. Chou¹ and Cong-Qiu Chu², ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Rheumatology, Oregon Health & Science Univ and Portland VA Medical Center, Portland, OR
Background/Purpose: Differentiation of naïve CD4+ T cells is considered to be an irreversible event and, in particular, the plasticity is thought to be completely lost…
Abstract Number: 836 • 2012 ACR/ARHP Annual Meeting
Clinical Responses and Patient Reported Outcomes to NNC0109-0012 (anti-IL-20 mAb) in Rheumatoid Arthritis (RA) Patients Following 12-Weeks Dosing and 13 Weeks Follow up: Results From a Phase 2a Trial
Ladislav ŠEnolt¹, Marie Göthberg², Xavier Valencia³ and Eva Dokoupilova⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Biostatistics, Novo Nordisk, A/S, Soeborg, Denmark, ³Clinical Medical and Regulatory Affairs, Novo Nordisk, Inc., Princeton, NJ, ⁴Medical Plus s.r.o, Uherske Hradiste, Czech Republic
Background/Purpose: NNC0109-0012 (anti-IL-20 mAb) is a novel human monoclonal IgG4 antibody which binds to and neutralizes the activity of IL-20. Data from a phase 1…
Abstract Number: 831 • 2012 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab (AMG 827) in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Karel Pavelka¹, Yun Chon², Richard Newmark², Ngozi Erondu³ and Shao- Lee Lin², ¹Institute of Rheumatology and Department of Rheumatology, 1st Medical Faculty, Charles University Prague, Prague, Czech Republic, ²Clinical Development, Amgen Inc, Thousand Oaks, CA, ³Amgen Inc, Thousand Oaks, CA
Background/Purpose: A potential role for IL-17 in rheumatoid arthritis (RA) has been supported by data from clinical studies of inhibitors of the IL-17A ligand. To…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].